Contrasting Rallybio (NASDAQ:RLYB) and Alector (NASDAQ:ALEC)

Rallybio (NASDAQ:RLYB) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.

Profitability

This table compares Rallybio and Alector’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-40.53%	-38.13%
Alector	-850.13%	-531.03%	-44.00%

Risk & Volatility

Rallybio has a beta of -0.72, suggesting that its stock price is 172% less volatile than the S&P 500. Comparatively, Alector has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.

Insider & Institutional Ownership

90.3% of Rallybio shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 10.3% of Rallybio shares are held by company insiders. Comparatively, 8.3% of Alector shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Rallybio and Alector”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$646,000.00	139.19	-$8.98 million	($4.34)	-3.90
Alector	$21.05 million	10.16	-$142.93 million	($1.10)	-1.74

Rallybio has higher earnings, but lower revenue than Alector. Rallybio is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Rallybio and Alector, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1	0	0	0	1.00
Alector	2	4	3	0	2.11

Alector has a consensus price target of $3.40, indicating a potential upside of 77.55%. Given Alector’s stronger consensus rating and higher probable upside, analysts clearly believe Alector is more favorable than Rallybio.

Summary

Alector beats Rallybio on 8 of the 14 factors compared between the two stocks.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

About Alector

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.